# PHASE 3 Biological Observation Audit

- RUN ID: 27
- CASE ID: 2
- SOURCE PHASE 2 RUN: 18
- STATUS: completed
- SCHEMA: phase3.0.1
- RULE: phase3-observation-v4
- PROMPT: biological_observation_extraction:v1

## Biological Observations

### Observation 1

CATEGORY: INFLAMMATORY
VARIABLE: night sweats
NORMALIZED VARIABLE: NIGHT_SWEATS
VALUE: NONE
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: At presentation
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "A 55-year-old woman presented with night sweats, cough, and hemoptysis."

### Observation 2

CATEGORY: METABOLIC
VARIABLE: FDG uptake
NORMALIZED VARIABLE: F_18_FLUORODEOXYGLUCOSE_UPTAKE
VALUE: very minimal FDG uptake with max SUV of 2.5
NORMALIZED VALUE: 2.5
UNIT: SUV
DIRECTION: DECREASED
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: Previously biopsied left lung nodule on F-18 FDG PET-CT
LINKED EVENT ID: 125
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "On the other hand, the previously biopsied left lung nodule has decreased in size and showed very minimal FDG uptake with max SUV of 2.5 (Fig. 3A and B)."

EVIDENCE 2 TYPE: OBSERVED_FACT
PAGE: 2
SECTION: Discussion
QUOTE: "Fig. 3 – Positron emission tomography–computed tomography images, 43 days later. The left lower lobe nodule (A) has decreased to 17 × 14 mm in size. On the fused image (B) it does not show increased uptake of F-18 ﬂudeoxyglucose."

### Observation 3

CATEGORY: METABOLIC
VARIABLE: maximum standardized uptake value (max SUV)
NORMALIZED VARIABLE: MAXIMUM_STANDARDIZED_UPTAKE_VALUE
VALUE: 15.2
NORMALIZED VALUE: 15.2
UNIT: SUV
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: Bilateral upper lobe cavitary lesions were markedly hypermetabolic on F-18 FDG PET-CT
LINKED EVENT ID: 125
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "The time interval between the baseline CT and PET-CT was 43 days. On F-18 FDG PET-CT, bi-lateral upper lobe cavitary lesions had increased in size and number and were markedly hypermetabolic with maximum standardized uptake value (max SUV) of 15.2 (Fig. 3C and D)."

### Observation 4

CATEGORY: OTHER
VARIABLE: complete blood count
NORMALIZED VARIABLE: COMPLETE_BLOOD_COUNT
VALUE: normal
NORMALIZED VALUE: normal
UNIT: NONE
DIRECTION: UNCHANGED
STATUS: REPORTED
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: At presentation
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "While the complete blood count was normal, the chest x-ray showed a well deﬁned round opacity in the left lower lobe (Fig. 1)."

### Observation 5

CATEGORY: OTHER
VARIABLE: cough
NORMALIZED VARIABLE: COUGH
VALUE: NONE
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: At presentation
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "A 55-year-old woman presented with night sweats, cough, and hemoptysis."

### Observation 6

CATEGORY: OTHER
VARIABLE: hemoptysis
NORMALIZED VARIABLE: HEMOPTYSIS
VALUE: NONE
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: At presentation
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "A 55-year-old woman presented with night sweats, cough, and hemoptysis."

### Observation 7

CATEGORY: OTHER
VARIABLE: left hilar nodal spread
NORMALIZED VARIABLE: HILAR_NODAL_METASTASIS
VALUE: NONE
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: PET-CT
LINKED EVENT ID: 125
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 2
SECTION: Discussion
QUOTE: "Fig. 3 – Positron emission tomography–computed tomography images, 43 days later. The left lower lobe nodule (A) has decreased to 17 × 14 mm in size. On the fused image (B) it does not show increased uptake of F-18 ﬂudeoxyglucose. (C) Bilateral upper lobe disease has increased (arrows). These show intensely increased ﬂudeoxyglucose uptake on positron emission tomography (D). Note left hilar nodal spread (arrowhead)."

### Observation 8

CATEGORY: OTHER
VARIABLE: previously biopsied left lung nodule
NORMALIZED VARIABLE: LEFT_LOWER_LOBE_PULMONARY_NODULE_SIZE
VALUE: 27 × 23 mm to 17 × 14 mm
NORMALIZED VALUE: ['27 x 23', '17 x 14']
UNIT: mm
DIRECTION: DECREASED
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: Previously biopsied left lung nodule
LINKED EVENT ID: 129
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "On the other hand, the previously biopsied left lung nodule has decreased in size and showed very minimal FDG uptake with max SUV of 2.5 (Fig. 3A and B)."

EVIDENCE 2 TYPE: OBSERVED_FACT
PAGE: 2
SECTION: Discussion
QUOTE: "Fig. 2 – Representative images from the initial computed tomography, 10 days later. (A) Axial images in lung window shows a 27 × 23 mm left lower lobe nodule (arrow)."

EVIDENCE 3 TYPE: OBSERVED_FACT
PAGE: 2
SECTION: Discussion
QUOTE: "Fig. 3 – Positron emission tomography–computed tomography images, 43 days later. The left lower lobe nodule (A) has decreased to 17 × 14 mm in size."

EVIDENCE 4 TYPE: OBSERVED_FACT
PAGE: 3
SECTION: Discussion
QUOTE: "Interestingly, despite the recur-rence of disease, the biopsied lesion continued to decrease in size throughout the 19 months that followed after initial diagnosis."

### Observation 9

CATEGORY: OTHER
VARIABLE: melanoma recurrence with lung, brain, and spinal cord metastases
NORMALIZED VARIABLE: METASTATIC_MELANOMA_RECURRENCE
VALUE: resistant to ipilimumab
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: Following a favorable initial response to ipilimumab
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 3
SECTION: Discussion
QUOTE: "Our patient underwent immune therapy with ipilimumab with a favorable initial response. Unfortunately, as is common with this form of treatment, melanoma re-curred with lung, brain, and spinal cord metastases, this time resistant to ipilimumab."

### Observation 10

CATEGORY: OTHER
VARIABLE: bilateral upper lobe cavitary lesions
NORMALIZED VARIABLE: PULMONARY_CAVITARY_LESIONS
VALUE: increased in size and number
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: INCREASED
STATUS: REPORTED
TIME RELATION: DURING_REGRESSION
TEMPORAL PRECISION: RELATIVE
CONTEXT: F-18 FDG PET-CT
LINKED EVENT ID: 125
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "The time interval between the baseline CT and PET-CT was 43 days. On F-18 FDG PET-CT, bi-lateral upper lobe cavitary lesions had increased in size and number and were markedly hypermetabolic with maximum standardized uptake value (max SUV) of 15.2 (Fig. 3C and D)."

EVIDENCE 2 TYPE: OBSERVED_FACT
PAGE: 2
SECTION: Discussion
QUOTE: "Fig. 3 – Positron emission tomography–computed tomography images, 43 days later. The left lower lobe nodule (A) has decreased to 17 × 14 mm in size. On the fused image (B) it does not show increased uptake of F-18 ﬂudeoxyglucose. (C) Bilateral upper lobe disease has increased (arrows). These show intensely increased ﬂudeoxyglucose uptake on positron emission tomography (D). Note left hilar nodal spread (arrowhead)."

### Observation 11

CATEGORY: PATHOLOGIC
VARIABLE: CT-guided biopsy of the left lower lobe nodule
NORMALIZED VARIABLE: METASTATIC_MELANOMA
VALUE: positive for metastatic melanoma
NORMALIZED VALUE: positive
UNIT: NONE
DIRECTION: PRESENT
STATUS: REPORTED
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: Left lower lobe pulmonary nodule
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "A CT-guided biopsy of the left lower lobe nodule was positive for metastatic melanoma."

### Observation 12

CATEGORY: PATHOLOGIC
VARIABLE: primary lesion
NORMALIZED VARIABLE: PRIMARY_MELANOMA_LESION
VALUE: clinical examination did not reveal a primary lesion
NORMALIZED VALUE: NONE
UNIT: NONE
DIRECTION: ABSENT
STATUS: REPORTED_ABSENT
TIME RELATION: BEFORE_REGRESSION
TEMPORAL PRECISION: UNKNOWN
CONTEXT: Clinical examination after diagnosis of metastatic melanoma
LINKED EVENT ID: NONE
CONFIDENCE: 1.00

EVIDENCE 1 TYPE: OBSERVED_FACT
PAGE: 1
SECTION: Case Report
QUOTE: "Patient had no history of melanoma and clinical examina-tion did not reveal a primary lesion."

## Rejected As Interpretation

### Rejected Interpretation 1

STATEMENT: We suggest immune system modulation, triggered by biopsy, could have played a role, although the precise mechanism remains unknown.
REASON: Author hypothesis about a mechanism; it does not directly measure immune modulation or establish that biopsy caused regression.
PAGE: 1
SECTION: Title
QUOTE: "We suggest immune system modulation, triggered by biopsy, could have played a role, although the precise mechanism remains unknown."

### Rejected Interpretation 2

STATEMENT: We postulate that trauma from biopsy could have induced an inflammatory response and lead to subsequent regression of this lesion although the mechanism leading to this rare phenomenon remains obscure.
REASON: Author postulate of a biopsy-induced inflammatory mechanism; no inflammatory response was directly documented for this patient.
PAGE: 3
SECTION: Discussion
QUOTE: "We postulate that trauma from biopsy could have induced an inﬂammatory response and lead to subsequent regres-sion of this lesion although the mechanism leading to this rare phenomenon remains obscure."

## Summary

- OBSERVATIONS: 12
- VERIFIED EVIDENCE: 18
- REJECTED EVIDENCE: 2
- DUPLICATE MERGES: 0
- UNCERTAIN: 0
- NOT REPORTED TARGETS: 37
